1-5 of 5
Anirudh Prahallad
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Clinical Trials & Observations
Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St Pierre, Anirudh Prahallad, Cristina Diaz-de-Heredia
Journal: Blood
Blood (2024) 144 (20): 2095–2106.
https://doi.org/10.1182/blood.2023022565
Published: 2024
Includes: Supplemental data
Journal Articles

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser
Journal: Blood
Blood (2023) 141 (22): 2771–2779.
https://doi.org/10.1182/blood.2022018579
Published: 2023
Includes: Supplemental data
Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Florian H Heidel, Andrew Charles Perkins, Andreas Reiter, Carl C. Crodel, Caroline Hasselbalch Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Claire Harrison, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Bruyère Mahuzier, Jagannath Kota, Anirudh Prahallad, David M Ross
Journal: Blood
Blood (2022) 140 (Supplement 1): 590–593.
https://doi.org/10.1182/blood-2022-158501
Published: 2022
Journal Articles

Ruxolitinib in Pediatric Patients with Treatment- Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Pantelia Roussou, Annie St. Pierre, Anirudh Prahallad, Cristina Díaz-de-Heredia
Journal: Blood
Blood (2022) 140 (Supplement 1): 1376–1378.
https://doi.org/10.1182/blood-2022-155708
Published: 2022
Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Gérard Socié, MD PhD, Dietger Niederwieser, MD PhD, Nikolas Von Bubnoff, Mohamad Mohty, MD PhD, Jeffrey Szer, MBBS, Reuven Or, MD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Eva Maria Wagner, MD, Edouard Forcade, MD PhD, Jaime Sanz Caballer, MD PhD, Domenico Russo, MD, Giovanni Grillo, MD, Tsila Zuckerman, MD, Sinem Civriz Bozdag, MD, David Ritchie, MD ChB, PhD FRACP, FRCPA, Shalini Chaturvedi, Anirudh Prahallad, PhD, Karen Sinclair, PhD, Celine Wilke, MD, Robert Zeiser, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140403
Published: 2020